Increased flexibility seen in preapproval evidence for new drugs

The characteristics of acceptable preapproval evidence were more flexible for novel drugs approved by the U.S. Food and Drug Administration in 2020, according to a research letter published online May 17 in JAMA Network Open.
The characteristics of acceptable preapproval evidence were more flexible for novel drugs approved by the U.S. Food and Drug Administration in 2020, according to a research letter published online May 17 in JAMA Network Open.